These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36416118)

  • 1. BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.
    Verstovsek S; Al-Ali HK; Mascarenhas J; Perkins A; Vannucchi AM; Mohan SR; Scott BL; Woszczyk D; Koschmieder S; García-Delgado R; László R; McGreivy JS; Rothbaum WP; Kiladjian JJ
    Future Oncol; 2022 Nov; ():. PubMed ID: 36416118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth
    Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
    Cancer Res Commun; 2022 Sep; 2(9):1075-1088. PubMed ID: 36922937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Macrophage Inhibitory Cytokine-1 Pharmacodynamics of the Murine Double Minute 2 Inhibitor, Navtemadlin (KRT-232) in Fed and Fasted Healthy Subjects.
    Wong S; Krejsa C; Lee D; Harris A; Simard E; Wang X; Allard M; Podoll T; O'Reilly T; Slatter JG
    Clin Pharmacol Drug Dev; 2022 May; 11(5):640-653. PubMed ID: 35172043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes.
    Mascarenhas JO; Verstovsek S
    Cancer; 2022 Jul; 128(14):2717-2727. PubMed ID: 35385124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design.
    Mascarenhas J; Harrison CN; Kiladjian JJ; Komrokji RS; Koschmieder S; Vannucchi AM; Berry T; Redding D; Sherman L; Dougherty S; Peng L; Sun L; Huang F; Wan Y; Feller FM; Rizo A; Verstovsek S
    Future Oncol; 2022 Jul; 18(22):2393-2402. PubMed ID: 35510486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A population pharmacokinetic-pharmacodynamic model of navtemadlin, its glucuronide metabolite (M1) and serum macrophage inhibitory cykokine-1 (MIC-1).
    Zhang L; Poland B; Green M; Wong S; Slatter JG
    Xenobiotica; 2022 Jun; 52(6):555-566. PubMed ID: 36052821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
    Talpaz M; Kiladjian JJ
    Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelofibrosis: challenges for preclinical models and emerging therapeutic targets.
    Morsia E; Gangat N
    Expert Opin Ther Targets; 2021 Mar; 25(3):211-222. PubMed ID: 33844952
    [No Abstract]   [Full Text] [Related]  

  • 9. SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis.
    Chifotides HT; Bose P; Masarova L; Pemmaraju N; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):210-223. PubMed ID: 34840087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitation of navtemadlin in human plasma and brain tissue by liquid chromatography-tandem mass spectrometry.
    Kagan AB; Anders NM; Hemingway A; Lee EQ; Kelly KR; Lee HC; Xu-Welliver M; Piekarz R; Rudek MA
    Biomed Chromatogr; 2022 Nov; 36(11):e5467. PubMed ID: 35895384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials.
    Tremblay D; Hoffman R
    Expert Opin Emerg Drugs; 2021 Dec; 26(4):351-362. PubMed ID: 34875179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study.
    Mead AJ; Butt NM; Nagi W; Whiteway A; Kirkpatrick S; Rinaldi C; Roughley C; Ackroyd S; Ewing J; Neelakantan P; Garg M; Tucker D; Murphy J; Patel H; Bains R; Chiu G; Hickey J; Harrison C; Somervaille TCP
    Ther Adv Hematol; 2022; 13():20406207221084487. PubMed ID: 35371428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms.
    Bose P; Masarova L; Verstovsek S
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33050168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.
    Bose P; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):641-649. PubMed ID: 34272171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruxolitinib for the treatment of myelofibrosis: its clinical potential.
    Ostojic A; Vrhovac R; Verstovsek S
    Ther Clin Risk Manag; 2012; 8():95-103. PubMed ID: 22399854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing myelofibrosis (MF) that "blasts" through: advancements in the treatment of relapsed/refractory and blast-phase MF.
    Scherber RM; Mesa RA
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):118-126. PubMed ID: 30504300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruxolitinib for myelofibrosis--an update of its clinical effects.
    Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next Generation Therapeutics for the Treatment of Myelofibrosis.
    Tremblay D; Mascarenhas J
    Cells; 2021 Apr; 10(5):. PubMed ID: 33925695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors.
    Waksal JA; Mascarenhas J
    Curr Hematol Malig Rep; 2022 Oct; 17(5):140-154. PubMed ID: 35984598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
    Pemmaraju N; Bose P; Rampal R; Gerds AT; Fleischman A; Verstovsek S
    Leuk Lymphoma; 2023 Jun; 64(6):1063-1081. PubMed ID: 37081809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.